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Summary Prior analysis of 20 human mesothelioma cell lines for p53 status revealed only two mutations and
one p53 null cell line, although p53 expression was detected in most cell lines. In addition, mRNA and protein
expression of the retinoblastoma gene product in human mesothelioma cell lines is similar to normal controls.
We have tested for p53 induction after exposure to ionising radiation and demonstrate this induction and, to a
lesser extent, p2IWAFI induction, in both normal mesothelial cells and p53-positive mesothelioma cell lines. We
postulated that high levels of MDM2 might alter p53 and retinoblastoma tumour-suppressor function in
mesothelioma. However, Southern blot analysis for mdm2 indicated that no amplification had occurred in 18
mesothelioma cell lines tested. Steady-state mRNA and protein levels also did not indicate overexpression.
These results indicate that high levels of MDM2 are not responsible for inactivating the functions of wild-type
p53 or the retinoblastoma gene product during the pathogenesis of malignant mesothelioma.
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Mesothelioma, a cancer involving disregulation of mesothe-
lial cell growth, has been linked epidemiologically to asbestos
fibre exposure (Wagner 1960; Wagner and Berry, 1969;
Craighead and Mossman, 1982). The 20-50 year duration of
the latency period for this malignancy suggests that it is
generated by a multistep process induced by fibre exposure
and involving chromosome breakage, rearrangement and
deletions (Barrett, 1991; Hei et al., 1992), aneuploidy
(Lechner et al., 1985) and mutations secondary to damage
by reactive oxygen species (Mossman et al., 1986). At a
molecular level, the pathogenesis of the disease is likely to
involve modulation of tumour-suppressor pathways that are
critical for normal cellular regulation.
Alterations in the p53 tumour-suppressor gene have been
identified as the most frequent genetic events in a wide
variety of human cancers (Hollstein 1991; Levine et al., 1991;
Vogelstein and Kinzler, 1992). In addition, retinoblastoma
(Rb) gene dysfunction has been implicated in carcinogenesis
(Benedict et al., 1990). The importance of p53 and Rb
tumour-suppressor function is shown by the evolution, in
DNA tumour viruses, of proteins which disrupt the function
of these molecules. Interaction of p53 and Rb with SV40 T
antigen (Farmer et al., 1992; Mietz et al., 1992; Jiang et al.,
1993; DeCaprio et al., 1988), adenovirus Ela and Elb (Yew
and Berk, 1992; Whyte et al., 1988), and papillomavirus E6
and E7 (Mietz et al., 1992; Dyson et al., 1989) has been
shown to block wild-type functions of these molecules.
Indeed, in recent work showing the presence, in mesothelio-
ma specimens, of SV40 T antigen (Carbone et al., 1994), the
authors suggest that latent SV40 infection of mesothelial cells
may contribute to development of mesothelioma.
In contrast, the cell lines studied in this report have been
shown previously to be negative for SV40 T antigen in a
study in which all cells were stained with the polyclonal
antibody to SV40 T, Pab 416, as an isotype-matched negative
control for the p53 antibodies, Pab 1801 and 122 (Metcalf et
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al., 1992). That study established, by sequencing, in most
cases, exons 2-11 of the p53 gene, that the cell lines with
wild-type p53 genes (18/20), as well as two normal samples
examined, expressed a detectable level of p53 protein. One
hypothetical explanation for this observation involves over-
expression of a cellular protein, which can inhibit the
function of the p53 protein.
A candidate cellular protein, mouse double-minute 2
(MDM2), was cloned from the tumorigenic cell line,
3T3DM, and shown to have oncogenic potential (Cahilly-
Snyder et al., 1987; Fakharzadeh et al., 1991). MDM2,
through its N terminus (Chen et al., 1993; Oliner et al., 1993),
binds to the transactivation domain of p53 and interferes
with its activity as a transcriptional activator (Zauberman et
al., 1993; Finlay, 1993; Momand et al., 1992). Furthermore,
induction of transformed foci in rat embryo fibroblasts by
overexpression of ras and MDM2 is reduced by 50% by co-
transfection with a wild-type p53 vector, and transformed
cells express low levels of the wild-type p53 protein (Finlay,
1993). Overexpression of mdm2, in the presence of wild-type
p53, has been demonstrated in metastatic osteosarcomas
(Ladanyi et al., 1993), a low percentage of non-small-cell lung
carcinomas (Marchetti et al., 1995), a subset of human
malignant gliomas (Reifenberger et al., 1993) and human
leukaemias (Bueso-Ramos et al., 1993; Quesnel et al., 1994;
Zhou et al., 1995).
The mdm2 gene, in mouse, has been shown to produce
several sets of proteins (Olson et al., 1993; Barak et al., 1993)
resulting from alternative splicing (Wu et al., 1993; Haines et
al., 1994), and/or alternative promoter usage (Barak et al.,
1994). It has been shown that initiation of translation from
the third and fourth initiation codons results in molecules
unable to bind to p53 (Olson et al., 1993; Haines et al., 1994).
The conservation of a p53-responsive element leading to
alternative transcripts has been demonstrated in the human
mdm2 gene (Zauberman et al., 1995), but its protein products
remain to be characterised.
It has been suggested that MDM2 species that bind to p53
may be involved in an autoregulatory feedback loop (Wu et
al., 1993; Perry et al., 1993; Barak et al., 1994; Picksley and
Lane, 1993). This feedback control would function by
stimulation of mdm2 transcription by p53 from the p53-
dependent promoter in intron 1, as opposed to theMDM2 in human mesothelioma cell lines
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constitutive, upstream promoter (Wu et al., 1993; Barak et
al., 1994; Zauberman et al., 1995). Increased levels of MDM2
protein reduce p53 stimulation of the p53 response element in
the mdm2 gene (Wu et al., 1993), and inhibit the ability of
irradiated colorectal carcinoma (RKO) and osteosarcoma
(OSA-Cl) cell lines to arrest in the GQ stage of the cell cycle
(Chen et al., 1993).
Previous work from this laboratory has demonstrated that
both Rb mRNA and protein are expressed in malignant
mesothelioma cell lines and primary cultures of NHM cells
(Van der Meeren et al., 1993). In addition, the presence of
immunohistochemically detectable Rb protein in paraffin-
embedded tissue from human mesothelioma specimens and
normal human mesothelium has been reported (Ramael et al.,
1994). These observations suggest that a downstream
inactivator of Rb, as well as p53, could be crucial in
mesothelial carcinogenesis. MDM2 has now been shown to
bind to Rb as well as p53 (Xiao, ZX et al., 1995). The
function of Rb would be additionally compromised by the
binding of MDM2 to the transcription factors E2F1/DPI
with consequent enhancement of their activation functions
(Martin et al., 1995). Thus, disruption of cellular home-
ostasis, secondary to overexpression of mdm2, could lead to
disregulated cell growth by: (1) inactivation of p53 tumour-
suppressor activity; (2) interference with E2F sequestration
on Rb; and (3) activation of the S phase promoting
transcriptional factors, E2F1/DP1.
We, therefore, proposed that overexpression of the mdm2
gene product in malignant mesothelioma could result in a
functional inhibition of both the p53 and the Rb tumour-
suppressor pathways, leading to diminished control of the GI
checkpoint, even in the presence of functional p53 and Rb. A
previous immunohistochemical study of mesothelioma
demonstrated detectable MDM2 in six out of ten p53-
positive tumour specimens (Segers et al., 1995). We examined
the contribution of mdm2 gene amplification and/or protein
overexpression to mesothelial carcinogenesis by evaluating
mdm2 DNA content, as well as steady-state levels of mRNA
and protein in 18 of the mesothelioma cell lines previously
characterised for p53 (Metcalf et al., 1992) and comparing
these values with those obtained from primary cultures of
normal human mesothelial (NHM) cells.
Materials and methods
Cell lines and culture conditions
Human mesothelioma cell lines were cultured as described
previously (LaVeck et al., 1988). Detailed information on the
history and derivation of the M prefix cell lines has been
reported previously (Metcalf et al., 1992). Primary cultures of
NHM cells were obtained from patients with non-malignant
disease and initiated as described (LaVeck et al., 1988). OSA-
Cl, a sarcoma cell line lacking p53 mutation (Leach et al.,
1993) but exhibiting a 30- to 40-fold mdm 2 gene
amplification as well as overexpression of both mdm2
mRNA and protein (Oliner et al., 1992), was generously
supplied by Dr Bert Vogelstein. This cell line, as well as
human bronchial fibroblastic (HBF) cell strains, was
maintained in Hut medium (Roswell Park Memorial
Institute 1640 medium containing 10% fetal bovine serum;
BioFluids, Rockville, MD, USA). Normal human bronchial
epithelial (NHBE) cells were grown in LHC9 medium
(BioFluids Inc.) as described previously (Lechner and
LaVeck, 1985).
Exposure of cells to ionising radiation and
immunohistochemical analysis ofp53 and p21WAFI
NHM cells and mesothelioma cell lines were seeded in eight-
well chamber slides. Logarithmically growing cells were
subjected to 3.5 Gy of ionising radiation for 1 min and
returned to the incubator for 3 h. Cells were then fixed in 2%
paraformaldehyde [in phosphate-buffered saline (PBS)],
followed by methanol treatment. For simultaneous demon-
stration of p53 and p21WAFl expression, cells were doubly
labelled with CM-1 antibody (1:200 dilution, Signet
Laboratories, Dedham, MA, USA; rabbit IgG) and
monoclonal anti-p21WAFI antibody (1:50 dilution, Oncogene
Science, Uniondale, NY, USA; mouse IgG), followed by
fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG
and Texas red-conjugated anti-mouse IgG antibodies (1:300
dilution; Vector Laboratories, Burlingame, CA, USA). Nuclei
were stained with 4'6-diamidino-2-phenylindole (DAPI).
RNA isolation and Northern blot analysis
RNA was isolated from logarithmically growing cells by the
method of Chomczynski and Sacchi (1987) and subjected to
Northern blot evaluation as described previously (Metcalf et
al., 1992). Filters were prehybridised at 65°C in Hybrisol I
(Oncor, Gaithersburg, MD, USA) for a minimum of 2 h and
then hybridised overnight with a random-primed 232P-
labelled 900 bp (-312 to approximately +600 relative to
ATG) XhoI restriction fragment from the MDM C14-2 clone
of the human mdm2 gene, kindly supplied by Dr Bert
Vogelstein (Oliner 1992). The filters were washed once at
room temperature with 2 x standard saline citrate (SSC),
1% sodium lauryl sulphate (SDS), and then at 65°C twice
with 2 x SSC, 1% SDS, twice with 1 x SSC, 1% SDS, twice
with 0.5 x SSC, 1% SDS, and once at room temperature
with 0.1 x SSC. RNA loading and integrity were verified by
either concurrent or sequential probing of the filters with a
random-primed a32P-labelled 900 bp PstI restriction fragment
of a clone of the rat glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) gene (Fort et al., 1985), generously
provided by Dr Marc Piechaczyk. Several exposures of each
membrane were scanned on a Molecular Dynamics laser
densitometer (Sunnyvale, CA, USA). Volumes for each band
of mdm2 RNA were calculated and normalised to volumes
for the GAPDH band in the same lane on the same filter.
These ratios were then compared with mdm2/GAPDH ratios
for the VAMT-1 mesothelioma cell line. Since VAMT-1 cells
are null for p53 expression (Metcalf et al., 1992), these cells
were chosen to provide a constitutive MDM2 expression level
(Zauberman et al., 1995) for comparison. Interestingly, the
MDM2 expression in this cell line was equivalent to that in
the normal HBF cell strain used for protein normalisation.
All expression ratios are arbitrary numbers and have not
been normalised to an absolute concentration standard.
Protein extraction and Western blot analysis
Lysates were prepared, from logarithmically growing cells, as
the supernatant fraction of a 30 min, 4°C centrifugation at 38
600 xg in a buffer containing 50 mM Tris, pH 7.4, 150 mM
sodium chloride, 1% (v/v) Triton-X-100, 1% deoxycholic
acid (v/v), 0.1% SDS, 0.1 mM dithiothreitol and 0.57 mM
phenylmethylsulphonyl fluoride. Routinely, samples contain-
ing 100 ,ig of protein, determined using the BCA Reagent
(Pierce, Rockford IL, USA), were separated by 7.5% Sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to Immobilon-P (Millipore, Bedford,
MA, USA) membranes, probed with the anti-human MDM2
AB-1 (Oncogene Science, Uniondale, NY, USA) and detected
by chemiluminescence using the Renaissance (Dupont/NEN,
Boston, MA, USA) reagents and protocol. This anti-MDM2
antibody recognises an epitope in the amino terminus
between residues 26 and 150 and would detect the p53-
binding protein species (Olson et al., 1993; Haines et al.,
1994). The membranes were reprobed, without stripping, with
an anti-Rb rabbit polyclonal IgG, RB(C-15) (Santa Cruz
Biotech, Santa Cruz, CA, USA). Protein loading for OSA-Cl
was reduced to 25 Mg. A series ofdilutions for OSA-Cl lysate,
10-100 pg (data not shown), established the linear range for
protein densitometry and demonstrated that the Rb signal
per jug lysate protein was similar for all mesothelioma cells
tested. Since the Rb protein product is expressed at similarMDM2 in human mesothelioma cell lines
S Ungar et al
levels iln mesothelioma cell lines and NHM cells (Van der
Meeren ct al., 1993), Rb was used as the internal control for
protein loading. MDM2/'Rb ratios were calculated as
described for mRNA and normalised to those obtained for
HBF cells without conversion to an absolute concentration
stanidard.
DNA isolation aci;l Soltlhcr;i blot analysis
DNA was extracted, digested with EcoRI, and analysed by
Southern blotting (Maniatis ct al., 1982). Membranes were
probed with an f3'P-labelled nmdnI2 cDNA fragment, as
described for RNA analysis. DNA loading and integrity were
verified by reprobing with a randonm primed "P-labelled
900 bp Sau3AI fragmenit of the human single copy gene, J,,,
generously provided by Dr Philip Leder (Ravetch et al.,
1981a). The 4.6 kb and/or 8.8 kb banids of muhni2 DNA were
normalised to values for the 22 kb JIJ band in the same lane
on the same filter. These ratios were then compared with
mdl,n2 J1, DNA content in HBF cells as described for
Northerni blot analysis.
Results
Although the mesothelioma cell lines investigated here have
been characterised for p53 expression (Metcalf et alt., 1992),
assays indicating biological function have not been reported.
Therefore, we tested the ability of p53 to be induced by DNA
damiiagc, as demonstrated in most cell types (Kuerbitz et al.,
1992; Lu and Lane, 1993). Selected mesothelioma cell lines
with a basal level of detectable, wild-type p53 (Metcalf et al.,
1992) were compared with NHM and the p53 null cell line,
VAMT-1, for induction of' nuclear p53 and p2l1Al in
response to ionising radiation. Figure 1 presents the data,
which are illustrated photographically in Figure 2 for NHM
cells and the mesothelioma lines, M33K and VAMT-1. The
M33K cell line is representative of'mesotheliomas that express
wild-type p53 at a low, but detectable, level in the absence ofT
antigen, while VAMT-l cells are null for p53 expression. Both
M33K and VAMT-I are wild-type in exons 2 -I by sequence
analysis (Metcalf'et al., 1992). Cells were scored as positive for
inductionl, when p53 or p21" I'AF' showed nuclear accumulation
as defined by the DAPI staiin. In both NHM and M33K cells,
ionising radiation induces nuclear accumulation of p53 and
_ ""'. Mairked cells in NHM and M33K panels illustrate
positive, nuclear accumulation of the induced protein. The
lower marked cell in the M33K was scored positive for p53
and negative for p2 1AF' induction. The VAMT-1 cells
illustrate the appearance of background staining for both
proteins. Figure 1 displays the data obtained by counting cells
showing nuclear staining on either irradiated or control slides.
Five of the six mesothelioma lines analysed here showed
significant, colocalised (Figure 1) induction ofp2lWAFI as well
as p53. Values for irradiated VAMT-l cells and control M24K
cells were not significant. Interestingly, the M28K cell line did
not demonstrate nuclear p53 in control or irradiated speci-
mens, suggesting that this p53-expressing cell line may have a
defe'ct in induction of the protein by DNA damage. The
positive response of five of six mesotheliomas supports the
hypothesis that the p53 tumour suppressor is functional as a
DNA damage sensor (transcription factor) in the majority of
mesothelioma cells.
To investigate the possibility that amplification of the
i(ndin2 gene, and subsequent elevation of tndm2 expression,
could rcsult in intcrference with the p53 and Rb tumour-
suppressor pathways in malignant mesothelioma, 18 malig-
nant mesothelioma cell lines were assayed for mdni2 gene
content relative to HBF by Southern blot analysis (Table I).
None of the samples showed inmbn2 gene rearrangements. The
;nd,n2 gene content of mesothelioma cell lines relative to
HBF, ranged from 1.0 to 1.7 (Table I), suggesting that the
,ndmn2 gene is not amplified in malignant mesothelioma cell
lines.
Since overexpression of mRNA could lead to increased
levels of protein expression, four primary cultures of NHM
cells, one primary culture of HBF cells and 18 malignant
mesothelioma cell lines (Table I, Figure 3) were evaluated for
steady-state levels of mdm2 mRNA. All of these specimens
revealed a single message of 5.5 kb, consistent with the size of
mdm2 mRNA previously reported (Ladanyi et al., 1993;
Oliner et al., 1992) (Figure 3). The presence of multiple
mRNA species (Zauberman et al., 1995) was not detected in
these cells. Analysis of the four NHM revealed a range of
mdm2 mRNA levels with three samples from 1.4 to 3.6 as
much mRNA as VAMT-1, and one outlier at a 10.5-fold
excess (Table I). Nothing in the donor history or culture
characteristics of this NHM culture explained this observa-
tion. Steady-state levels of MDM2 mRNA in the malignant
mesothelioma cell lines ranged from 1.1 to 5.1, relative to
VAMT-1 (Figure 3, Table I). Figure 3 illustrates MDM2
steady-state mRNA levels in representative mesothelioma
(lanes 1 -5), NHM (lanes 6 and 7), HBF (lane 8) and
overexpressing OSA-Cl (lane 9) cells.
a
a, I0
o- Cf) 0
C-
UC)
0
-0
a)
0~
a
CN4
a.
Figure 1 Induction of (a) p53 and (b) p21WAF1 in NHM and
mesothelioma cell lines. The specified cell cultures were treated
(-) or mock treated (D-) with 3.5Gy for I min and then
incubated at 37 C for 3 h. Cells were treated as detailed in
Materials and methods, and the p53- and p21wAl1-positive cells
were enumerated visually on a fluorescence microscope. Values
are presented as the percentage of total cells counted. These totals
were: NHM ', 530; NHM , 800; VAMT-l , 202; VAMT-l-
309; M33K ', 201; M33K -, 310; MlOK , 296; MlOK 471;
M14K.+ 220; M14K-, 268; M25K ', 108; M25K 256;
M24K , 175 M24K 319; M28K ? 174; M28K-, 393.
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Figure 2 p53 and p21WAFI are induced in NHM and mesothelioma cells by ionising radiation. Nuclei were visualised by staining with
DAPI, p53 with fluorescein and p21WAFI with Texas red. Irradiated cultures and mock-irradiated controls are illustrated for NHM, M33K
and VAMT-1. +, Cells which received 3.5 Gy for I min; -, mock-irradiated control cells. Arrows in the p53 and p21IWAFI panels for NHM
illustrate induced cells. In the M33K panels, both marked cells are positive for p53 induction, while positive induction is illustrated by the
upper cell and negative induction by the lower cell in the p21WAFI panel. The VAMT-1 cells, which do not express p53 protein, are included
to illustrate the appearance of background membrane staining.
Table I Analysis of MDM2 in human mesothelioma cell lines
Cell line
M33K
M24K
M25K
M20
M32K
M28K
VAMT-1
M14K
M19
M9K
Hut290
Hut28
MIOK
Ml 5K
JMN
DND
MT3
M14M
HBF
OSA-Cl
p53b
Wt (2- 11)
Wt (2- 11)
Wt (2- 11)
Wt (2- 11)
Wt (2- 11)
Wt (2- 11)
Null (2-11)
Wt (2-11)
Wt (2-11)
Wt (5-9)
Wt (4- 11)
Wt (2- 11)
Wt (2-11)
Mt (4-11)
Mt (4- 11)
Wt (2-11)
Wt (5-9)
Wt (2- 11)
ND
ND
MDM2a
mRNA DNA
4.0
5.1
2.1
2.7
1.8
2.1
1.0
4.5
3.9
4.0
2.3
1.5
1.5
1.6
1.3
1.0
3.0
4.7
1.0
21
1.0
1.4
1.0
1.1
1.1
1.0
1.1
1.0
1.0
1.2
1.0
1.2
1.3
1.1
1.0
1.0
1.2
1.7
1.0
35.4
Protein
4.6
4.2
5.8
2.3
3.8
2.3
0.1
4.5
4.0
3.9
2.1
4.2
1.2
2.1
1.1
1.5
4.4
5.2
1.0
50
aAutoradiograms from several different exposures of membranes
were analysed by densitometry. Values were calculated as described in
Materials and methods and normalised to HBF3898 for DNA and
protein, and to VAMT-1 for mRNA values. bExons sequenced. Wt,
wild-type; mt, mutant; ND, not done.
Finally, since MDM2 protein expression may be con-
trolled at the post-translational level (Landers et al., 1994),
the steady-state level of MDM2 protein was studied in the
mesothelioma cell lines, five NHM isolates, one culture of
HBF cells and two primary NHBE cell strains by Western
blot analysis (Table I, Figure 4). A single band of 90 kDa
(Figure 3), similar in size to that previously reported for the
MDM2 protein product (Leach et al., 1993; Oliner et al.,
1992; Barak and Oren, 1992; Momand et al., 1992; Haines et
al., 1994) and consistent with the single mRNA species, was
observed in all samples tested. The five NHM cell samples
demonstrated a protein range of 1.2 to 9.8, relative to HBF
(data not shown) with the highest value corresponding to the
cell strain with the highest mRNA level. The 18 malignant
mesothelioma cell lines exhibited protein levels ranging from
0.1 to 5.8, relative to HBF (Table I). In general, the level of
MDM2
GAPDH
Figure 3 Steady-state MDM2 mRNA levels in human mesothe-
lial cells and mesothelioma cell lines. Total cellular RNA (20,ug
was analysed by Northern blotting as described in Materials and
methods. The membranes were hybridised either serially or in
combination with probes for MDM2 and GAPDH. Ratios of
mRNA levels are shown in Table I relative to VAMT-l (lane 1), a
p53 null mesothelioma cell line. The data shown are illustrative of
both malignant mesothelioma cell lines (lanes 1 -5), primary
cultures of NHM (lane 6, NHM I = UMD10348 and lane 7,
NHM 2 = GU931028), primary fibroblastic cells (lane 8
HBF3898) and the overexpressing OSA-Cl line (lane 9).
MDM2
Rb -
Figure 4 Steady-state protein levels of MDM2 and Rb in normal
human cells and mesothelioma cell lines. Total cellular protein
(100,ug) was analysed by Western blotting as described in
Materials and methods. The membranes were probed with
antibody to MDM2 and visualised with chemiluminescence.
Membranes were then reprobed with antibody to Rb as detailed
in Materials and methods. Representative samples of steady-state
protein lysates probed for MDM2 and Rb are shown. Lanes 1 - 5
are malignant mesothelioma cell lines, lanes 6 and 7 are NHM
(NHM 1 = UMD10227, NHM 2 = GU931028), lane 8 is NHBE
3883, lane 9 is HBF3898 and lane 10 is OSA-Cl. Lanes 1 -9
contain 100ljg protein, while lane 10 (OSA-Cl) contains 25jg
protein. MDM2 values relative to Rb are reported in Table I.
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protein expression was consistent with the steady-state
mRNA level observed (Table I). The samples shown in
Figure 4 are representative of steady-state protein expression
in mesothelioma cell lines (lanes 1 -5), NHM (lanes 6 and 7),
NHBE (lane 8), HBF (lane 9) and OSA-C1 (lane 10). All of
the mesothelioma cell lines demonstrate MDM2 protein
levels within the range of normal human cells, except for
the VAMT-1 cell line, which shows a 10-fold reduction in
MDM2 protein level when compared with HBF. This
observation might indicate the presence of p53-stimulated
mdm2 transcription in the other cell lines (Zauberman et al.,
1995). Reprobing the membranes with anti-Rb antibody
revealed a band at approximately 115 kDa (Figure 4). In
other experiments (data not shown), addition of phosphatase
inhibitors before cell lysis revealed the multiply phosphory-
lated Rb species in mesothelioma and HBF. Semi-quantita-
tive comparison of Rb protein in mesothelioma cell lines and
primary cultures of normal cells revealed similar amounts of
the Rb protein product per jug protein analysed, relative to
HBF (1.06+0.36 s.d., n=18 and 1.32+0.5 s.d., n=8
respectively).
Discussion
It has been reported that loss of p53 tumour-suppressor
activity in a variety of human cancers with low frequency of
p53 mutation, has been associated with amplification of the
mdm2 gene and/or increases in MDM2 mRNA and protein
levels (Leach et al., 1993; Oliner et al., 1992; Barak and Oren,
1992; Momand et al., 1992). An extensive study of soft-tissue
sarcomas (Cordon-Cardo et al., 1994) indicated a complex
pattern of mdm2 overexpression that did not result solely
from gene amplification and existed even in the presence of
p53 mutations and overexpression. Current data indicate that
overexpression of the MDM2 protein could lead not only to
(1) inactivation ofp53 tumour-suppressor activity, but also to
(2) interference with E2F binding on Rb and (3) activation of
the E2F/DP1 transcriptional factors (Haines et al., 1994;
Xiao et al., 1995; Martin et al., 1995), resulting in the loss of
G, checkpoint regulation by p53 and Rb. It has been
demonstrated that Rb is expressed in malignant mesothelio-
ma cell lines and tumours (Van der Meeren et al., 1993;
Ramael et al., 1994) (Figure 4) and that p53 mutation is an
infrequent event (Metcalf et al., 1992). Furthermore,
exposure of NHM and mesothelioma lines expressing wild-
type p53 to ionising radiation induces nuclear accumulation
of p53 and p2lWAFl in five of six lines tested (Figures 1 and
2). These data indicate that the p53 observed by
immunohistochemical staining (Metcalf et al., 1992) is
responsive to DNA damage and able to activate the
p21WAFi gene transcriptionally in most mesothelioma cell
lines. Therefore, the possibility that the presence of mdm2
overexpression and/or amplification might be able to
compromise functions of p53 and Rb and inhibit G1
checkpoint regulation was examined in a series of
mesothelioma lines previously characterised for p53 and Rb
expression (Metcalf et al., 1992; Van der Meeren et al., 1993).
The relatively narrow range ofmdm2 gene content, relative to
HBF (Table I), indicates that the mdm2 gene is not amplified
in the malignant mesothelioma cell lines studied.
Steady-state mdm2 protein and mRNA levels were also
evaluated in these cell lines. The few NHM samples available
(n=4 for mRNA) does not allow sweeping generalisations
with respect to the 'normal range' of expression. Three of the
four samples showed mRNA levels similar to the tumour cell
lines (1.4-3.6 relative to VAMT-1), while one sample showed
a 10.5-fold elevated expression (Figure 3, lane 6). mRNA
levels in malignant mesothelioma cell lines (Table I) ranged
from 1.0 to 5.1 relative to VAMT-1, a variation which was
similar to the NHM cells. Previous studies of NHM cells
showed that they exhibit broad interindividual variation in
other biological properties (LaVeck et al., 1988; Lechner et
al., 1989). Therefore, the variation observed is not likely to
represent biologically significant overexpression. Since it has
been demonstrated that the human mdm2 gene contains a
functional, p53-responsive promoter (Zauberman et al.,
1995), a correlation between levels of wild-type p53 and
MDM 2 expression in mesothelioma cell lines might be
expected. Elevated expression of wild-type p53 protein in the
M9K, M32K and DND cell lines has been inferred from
results of immunocytochemistry (Metcalf et al., 1992).
However, these cell lines do not show consistently elevated
mdm2 mRNA levels (Table I). The p53 null VAMT-1 cells
show a low level of MDM2 protein but not of mRNA (Table
I). Furthermore, the M15K and JMN lines, which contain
mutant p53 genes, do not express low levels of MDM2
mRNA as might be expected if wild type p53 transcriptional
activation were important in maintaining the steady-state
mRNA level of this gene. These data are in agreement with
observations of others who report a lack of correlation
between levels of MDM2 mRNA and wild-type p53 protein
in a subset of human gliomas and the murine cell line, C127
(Reifenberger et al., 1993; Perry et al., 1993; Gudas et al.,
1995). This lack of correlation may reflect the complex
regulatory interactions, which are being delineated for the
genes and gene products involved in GI checkpoint
regulation.
While loss of function of tumour-suppressor gene
products has been implicated in the pathogenesis of a wide
variety of cancers, no alteration in expression of either the
p53 or Rb gene product has been demonstrated in this
laboratory in a high percentage (85% for p53 and 100% for
Rb) of malignant mesothelioma cell lines (Metcalf 1992; Van
der Meeren et al., 1993). Additionally, the results reported
here indicate that disruption of the wild-type p53 and Rb
tumour-suppressor pathways by high levels of MDM2
protein is not a major factor in the aetiology of malignant
mesothelioma. Thus, it is possible that uncharacterised
downstream factors in the p53 and/or Rb tumour-
suppressor pathways could be altered during the pathogen-
esis of malignant mesothelioma.
Recent studies have revealed an increasing number of
cellular proteins and DNA-binding proteins that interact with
p53. These include XPB and XPD, components of
transcription repair complex TFIIH (Wang et al., 1996);
CBF, a CCAAT binding factor; heat shock protein 70;
replication protein A; SPI, a general transcription factor;
TBP, a TATA binding protein; and WT1, the Wilms' tumour
gene product (for review see Pietenpol and Vogelstein, 1993).
Rb also has been found to interact with cellular proto-
oncogenes, cell cycle-related proteins and other transcrip-
tional factors, such as c-myc, N-myc, ATF-2, cdc2 proteins
(for review see Goodrich and Lee, 1993), cyclin D2 and
cyclin-dependent kinase 4 (CDK4) (Ewen et al., 1993). In
addition, alterations of proteins that modulate the activity of
these Rb-binding proteins, such as p16INK4, which inhibits
CDK4 phosphorylation of Rb (Ewen et al., 1993), could be
cellular components that participate in the loss of cell cycle
regulation. Recent data indicate that a large proportion of
mesothelioma cell lines (Okamoto et al., 1994; Cheng et al.,
1994), as well as primary mesothelioma tumours (Xiao, S et
al., 1995; Cheng 1994), have homozygous deletions of the p16
gene. Further studies of p16INK4 in primary mesothelioma
tumours will be necessary to evaluate the physiological
significance of the loss of p16INK4. In addition, other targets
in these tumour-suppressor pathways need to be evaluated to
advance the understanding of the pathogenesis of mesothe-
lioma.
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